Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM33 | Q9BZ11 | 8/20 | 0.82 |
| ▸ | ADAM17 | P78536 | 8/20 | 0.55 |
| ▸ | MMP1 | P03956 | 3/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | MMP14 | P50281 | 2/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998398 | 1.00 | ADAM33 (0.82) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL998393 | 0.91 | ADAM33 (0.83) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL998390 | 0.91 | ADAM33 (0.83) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL998691 | 0.90 | ADAM33 (1.00) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL2681556 | 0.90 | ADAM33 (0.79) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL2681561 | 0.90 | ADAM33 (0.79) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL998690 | 0.90 | ADAM33 (1.00) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL997001 | 0.90 | ADAM33 (0.83) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL997002 | 0.90 | ADAM33 (0.83) | ADAM33ADAM17MMP1MMP2MMP14 | |
| SCHEMBL996219 | 0.86 | ADAM33 (0.84) | ADAM33ADAM17MMP1MMP3ADAM9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448931-B1 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine | GALDERMA RES & DEV (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-8772478-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-08 | — | — | US | disclosed |
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2448931-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | Galderma Research & Development (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001088-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, STS | ADAM33 3905/4885ADAM17 3458/4885MMP1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.